AbCellera Biologics Inc. ABCL Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- AbCellera Biologics Inc. (ABCL) reported total cash, cash equivalents, and restricted cash (inclusive) of $103.8M in Q1 2026.
- How has AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive) decreased by 44.4% year-over-year, from $186.56M to $103.8M.
- What is the long-term trend for AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive)?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s total cash, cash equivalents, and restricted cash (inclusive) has grown at a -25.4% compound annual growth rate (CAGR), from $501.14M to $155.25M.